Stryker Invests $400 Million in CMR Surgical With Option to Acquire the Company Outright

Stryker announced a strategic equity investment of approximately $400 million in CMR Surgical, the Cambridge, U.K.-based robotics company behind the Versius surgical robotic system. Alongside the investment, Stryker secured an exclusive option to acquire the remaining equity of CMR Surgical at a future date, positioning it for a potential full takeover.

As part of the deal, Stryker will also serve as the exclusive U.S. commercial sales agent for CMR Surgical's Versius portfolio, giving it a direct role in launching the robot on the American market. Versius, which has been used in more than 30,000 surgical procedures worldwide, holds FDA authorization and is considered the second most adopted soft tissue surgical robot globally, trailing only Intuitive Surgical's da Vinci system.

The partnership gives Stryker a significant foothold in the fast-growing surgical robotics space without an immediate full acquisition, while providing CMR Surgical with capital and a powerful U.S. commercial partner to accelerate its domestic rollout.